European Society for Medical Oncology/LinkedIn
Mar 27, 2025, 14:45
SC pembrolizumab demonstrated noninferiority compared with IV pembrolizumab in the phase III MK-3475A-D77 trial – ESMO
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“As presented at ELCC25, subcutaneous (SC) pembrolizumab – consisting of pembrolizumab co-formulated with berahyaluronidase alfa – demonstrated noninferiority in pharmacokinetics compared with intravenous (IV) pembrolizumab in the phase III MK-3475A-D77 trial. Similar efficacy outcomes were observed.
Patients may prefer SC immunotherapy administration and other potential benefits include reductions in pharmacy preparation, nursing administration time, infusion-chair occupancy and infusion-related adverse events than with IV administration.
Results plus commentary in the ESMO Daily Reporter.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 29, 2025, 14:15
May 29, 2025, 13:35